Cranial Nerve Neoplasms: Clinical Trials

52 trials for Cranial Nerve Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

32 completed, 7 terminated, 4 active not recruiting, 4 not yet recruiting. 52 Phase 2, 8 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 252Completed 32, Terminated 7, Active not recruiting 4, Not yet recruiting 4, Recruiting 3, Unknown 2
Phase 18Active not recruiting 2, Completed 2, Not yet recruiting 2, Recruiting 1, Terminated 1
Phase 31Terminated 1

Follow Cranial Nerve Neoplasms: new trials by email Literature Review of Cranial Nerve Neoplasms trials Research Report on Cranial Nerve Neoplasms

Trials (filtered) newest first · largest first

All 52 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Selumetinib for NF2-Related Schwannomatosis
Selumetinib - Neurofibromatosis Type 2, NF2
Phase 2Not yet recruitingBeijing Tiantan Hospital202026-12-012026-10-28
Luvometinib in Combination With Serplulimab for NF2-Related Tumors
Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2
Phase 1 / Phase 2Not yet recruitingBeijing Tiantan Hospital302026-07-312026-07-16
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)
Selumetinib 25mg/m2, Luvometinib, Serplulimab - Neurofibromatosis Type 2, Vestibular Schwannoma
Phase 2Not yet recruitingBeijing Tiantan Hospital2002026-07-182026-07-20
Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II
Trineumin - Neurofibromatosis Type II, NF2
Phase 1 / Phase 2Not yet recruitingPRG Science & Technology Co., Ltd.252026-07-012026-01-23
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
AAVAnc80-antiVEGF via Akouos Delivery Device - Vestibular Schwannoma
Phase 1 / Phase 2RecruitingEli Lilly and Company272025-01-172026-11-04
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
RVP-001 - Central Nervous System (CNS) Lesions, Brain Metastases
Phase 2CompletedReveal Pharmaceuticals Inc.182024-08-152025-12-26
Doxycycline in Cutaneous Schwannoma (NF2)
Doxycycline Injection [Doxy] - Neurofibromatosis Type 2
Phase 1 / Phase 2Active not recruitingMassachusetts Eye and Ear Infirmary192022-09-192026-10-16
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
REC-2282, Placebo - Neurofibromatosis Type 2
Phase 2 / Phase 3TerminatedRecursion Pharmaceuticals Inc.252022-06-202026-08-17
Modified CV Regimen in Optic Pathway Glioma
Carboplatin, Vincristine, Recombinant human endostatin - Optic Glioma, Pediatric Brain Tumor, Optic Nerve Glioma
Phase 2RecruitingBeijing Sanbo Brain Hospital752022-04-132024-10-15
Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560
Fluorescein Sodium, YELLOW560 filter - Vestibular Schwannoma
Phase 2CompletedMayo Clinic122021-10-062023-08-01
Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System
tozuleristide, Canvas imaging system, Surgical resection of tumor - Central Nervous System Tumor
Phase 2CompletedJohn Yu502021-09-302026-07-10
Nimodipine in Vestibular Schwanommas
NiMODipine Injectable Solution, Placebo - Vestibular Schwannoma
Phase 2UnknownMedical University of Vienna302021-05-042023-10-19
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Brigatinib, Neratinib, Retifanlimab - Neurofibromatosis Type 2, Vestibular Schwannoma
Phase 2RecruitingScott R. Plotkin, MD, PhD1092020-06-202026-11-12
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Crizotinib - Neurofibromatosis 2, Progressive Vestibular Schwannoma (VS)
Phase 2CompletedUniversity of Alabama at Birmingham122020-02-182026-03-13
Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours
Selumetinib - Neurofibromatosis Type 1, Plexiform Neurofibroma
Phase 1 / Phase 2CompletedGreat Ormond Street Hospital for Children NHS Foundation Trust142019-09-262024-04-04
Study of Aspirin in Patients With Vestibular Schwannoma
Aspirin, Placebo - Vestibular Schwannoma, Acoustic Neuroma
Phase 2Active not recruitingMassachusetts Eye and Ear Infirmary972018-03-012026-10-16
RGD PET/MRI in Sporadic Vestibular Schwannoma
One injection of 68Ga-NODAGA-E[c(RGDyK)]2 - Acoustic Neuroma
Phase 2UnknownCopenhagen University Hospital, Rigshospitalet402018-01-022018-01-10
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
Laboratory Biomarker Analysis, Selumetinib Sulfate - Cutaneous Neurofibroma, Neurofibromatosis Type 1
Phase 2CompletedNational Cancer Institute (NCI)112017-08-262023-12-06
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
Selumetinib - Neurofibromatosis 2, Vestibular Schwannoma
Phase 2TerminatedChildren's Hospital Medical Center, Cincinnati102017-05-082025-04-22
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
AZD2014 - Neurofibromatosis 2, Meningioma
Phase 2CompletedMassachusetts General Hospital182016-08-312022-06-13

Showing 20 of 52. Sign in to see all of them.

Narrower conditions

Neurofibromatosis 2 (24)  ·  Neuroma, Acoustic (22)  ·  Optic Nerve Glioma (21)  ·  Astrocytoma (19)  ·  Oligodendroglioma (14)  ·  Central Nervous System Neoplasms (13)  ·  Meningioma (12)  ·  Brain Neoplasms (11)  ·  Medulloblastoma (10)  ·  Ependymoma (9)  ·  Familial ependymoma (9)  ·  Glioma (9)  ·  Glioblastoma (6)  ·  Neuroblastoma (6)  ·  Choroid Plexus Neoplasms (5)

Broader conditions

Cranial Nerve Diseases (52)  ·  Neoplasms by Histologic Type (52)  ·  Neoplasms, Nerve Tissue (52)  ·  Nervous System Diseases (52)  ·  Neuroectodermal Tumors (52)  ·  Neoplasms (51)  ·  Neoplasms, Germ Cell and Embryonal (50)  ·  Neoplasms by Site (46)  ·  Nervous System Neoplasms (46)  ·  Peripheral Nervous System Neoplasms (43)  ·  Nerve Sheath Neoplasms (34)  ·  Neuroendocrine Tumors (33)  ·  Otorhinolaryngologic Neoplasms (33)  ·  Otorhinolaryngologic Diseases (32)

Interventions

Bevacizumab (5)  ·  Carboplatin (5)  ·  AZD 6244 (4)  ·  Everolimus (3)  ·  Radiotherapy (3)  ·  Temozolomide (3)  ·  Doxorubicin (2)  ·  Endostatins (2)  ·  Irinotecan (2)  ·  Vincristine (2)  ·  etoposide phosphate (2)  ·  Aspirin (1)  ·  Axitinib (1)  ·  Blotting, Western (1)  ·  Cilengitide (1)

Sponsors

National Cancer Institute (NCI) (8)  ·  Beijing Tiantan Hospital (4)  ·  Duke University (3)  ·  NYU Langone Health (3)  ·  Children's Oncology Group (2)  ·  Massachusetts Eye and Ear Infirmary (2)  ·  Massachusetts General Hospital (2)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  University of Alabama at Birmingham (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Beijing Sanbo Brain Hospital (1)  ·  Children's Hospital Medical Center, Cincinnati (1)  ·  City of Hope Medical Center (1)  ·  Copenhagen University Hospital, Rigshospitalet (1)  ·  Eli Lilly and Company (1)

Countries

United States (39)  ·  Canada (8)  ·  China (6)  ·  Australia (4)  ·  New Zealand (4)  ·  Puerto Rico (4)  ·  Switzerland (3)  ·  Netherlands (2)  ·  United Kingdom (2)  ·  Austria (1)  ·  Denmark (1)  ·  France (1)

Top investigators

Henry S. Friedman, MD (3)  ·  Matthias A Karajannis, MD, MS (3)  ·  D. Bradley Welling, MD, PhD (2)  ·  Fu Zhao (2)  ·  Pinan Liu (2)  ·  Scott Plotkin, MD (2)  ·  Aaron Tward, MD (1)  ·  Andrew Cluster, M.D. (1)  ·  Anne-Marie Langevin, MD (1)  ·  Bruce R Korf (1)  ·  Darren Hargrave, MB Bch (1)  ·  Dorian Hirschmann, MD (1)  ·  Edward G. Shaw, MD (1)  ·  Girish Dhall, MD (1)  ·  Harry T Whelan, MD (1)

Results publications

PMID 16408203, PMID 17610262, PMID 18989154, PMID 20381270, PMID 26976425, PMID 35229827, PMID 36240730, PMID 37126770, PMID 38372904, PMID 38904277, PMID 38907342, PMID 40009403, PMID 41530428, PMID 42788739

NIH funding

U10CA098543 (5), 2017 (1), P30CA006973 (1), P30CA013148 (1), P30CA033572 (1), R44CA261240 (1), U10CA081920 (1), U10CA180886 (1)